166 related articles for article (PubMed ID: 22899477)
1. Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2-positive chronic eosinophilic leukemia.
Lierman E; Selleslag D; Smits S; Billiet J; Vandenberghe P
Blood; 2012 Aug; 120(7):1529-31. PubMed ID: 22899477
[No Abstract] [Full Text] [Related]
2. Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene.
Rumi E; Milosevic JD; Casetti I; Dambruoso I; Pietra D; Boveri E; Boni M; Bernasconi P; Passamonti F; Kralovics R; Cazzola M
J Clin Oncol; 2013 Jun; 31(17):e269-71. PubMed ID: 23630205
[No Abstract] [Full Text] [Related]
3. Chronic eosinophilic leukemia with erythroblastic proliferation and the rare translocation t(8;9)(p22;p24) with PCM1-JAK2 fusion gene: a distinct clinical, pathological and genetic entity with potential treatment target?
Prochorec-Sobieszek M; Nasiłowska-Adamska B; Borg K; Kopeć I; Kos-Zakrzewska K; Juszczyński P; Warzocha K
Leuk Lymphoma; 2012 Sep; 53(9):1824-7. PubMed ID: 22288769
[No Abstract] [Full Text] [Related]
4. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2.
Reiter A; Walz C; Watmore A; Schoch C; Blau I; Schlegelberger B; Berger U; Telford N; Aruliah S; Yin JA; Vanstraelen D; Barker HF; Taylor PC; O'Driscoll A; Benedetti F; Rudolph C; Kolb HJ; Hochhaus A; Hehlmann R; Chase A; Cross NC
Cancer Res; 2005 Apr; 65(7):2662-7. PubMed ID: 15805263
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene.
Rumi E; Milosevic JD; Selleslag D; Casetti I; Lierman E; Pietra D; Cavalloni C; Bellini M; Milanesi C; Dambruoso I; Astori C; Kralovics R; Vandenberghe P; Cazzola M
Ann Hematol; 2015 Nov; 94(11):1927-8. PubMed ID: 26202607
[No Abstract] [Full Text] [Related]
6. The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene.
Bousquet M; Quelen C; De Mas V; Duchayne E; Roquefeuil B; Delsol G; Laurent G; Dastugue N; Brousset P
Oncogene; 2005 Nov; 24(48):7248-52. PubMed ID: 16091753
[TBL] [Abstract][Full Text] [Related]
7. Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes.
Schwaab J; Knut M; Haferlach C; Metzgeroth G; Horny HP; Chase A; Tapper W; Score J; Waghorn K; Naumann N; Jawhar M; Fabarius A; Hofmann WK; Cross NC; Reiter A
Ann Hematol; 2015 Feb; 94(2):233-8. PubMed ID: 25260694
[TBL] [Abstract][Full Text] [Related]
8. t(8;9)(p22;p24)/PCM1-JAK2 activates SOCS2 and SOCS3 via STAT5.
Ehrentraut S; Nagel S; Scherr ME; Schneider B; Quentmeier H; Geffers R; Kaufmann M; Meyer C; Prochorec-Sobieszek M; Ketterling RP; Knudson RA; Feldman AL; Kadin ME; Drexler HG; MacLeod RA
PLoS One; 2013; 8(1):e53767. PubMed ID: 23372669
[TBL] [Abstract][Full Text] [Related]
9. Evolutional change of karyotype with t(8;9)(p22;p24) and HLA-DR immunophenotype in relapsed acute myeloid leukemia.
Huang KP; Chase AJ; Cross NCP; Reiter A; Li TY; Wang TF; Chu SC; Lu XY; Li CC; Kao RH
Int J Hematol; 2008 Sep; 88(2):197-201. PubMed ID: 18594780
[TBL] [Abstract][Full Text] [Related]
10. PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation.
Murati A; Gelsi-Boyer V; Adélaïde J; Perot C; Talmant P; Giraudier S; Lodé L; Letessier A; Delaval B; Brunel V; Imbert M; Garand R; Xerri L; Birnbaum D; Mozziconacci MJ; Chaffanet M
Leukemia; 2005 Sep; 19(9):1692-6. PubMed ID: 16034466
[No Abstract] [Full Text] [Related]
11. Myelodysplastic syndrome with t(9;22)(p24;q11.2), a BCR-JAK2 fusion: case report and review of the literature.
Kantarcioglu B; Kaygusuz-Atagunduz I; Uzay A; Toptas T; Tuglular TF; Bayik M
Int J Hematol; 2015 Sep; 102(3):383-7. PubMed ID: 25833723
[TBL] [Abstract][Full Text] [Related]
12. Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1.
Patterer V; Schnittger S; Kern W; Haferlach T; Haferlach C
Ann Hematol; 2013 Jun; 92(6):759-69. PubMed ID: 23400675
[TBL] [Abstract][Full Text] [Related]
13. Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study.
Tang G; Sydney Sir Philip JK; Weinberg O; Tam W; Sadigh S; Lake JI; Margolskee EM; Rogers HJ; Miranda RN; Bueso-Ramos C C; Hsi ED; Orazi A; Hasserjian RP; Arber DA; Bagg A; Wang SA
Mod Pathol; 2019 Apr; 32(4):490-498. PubMed ID: 30401948
[TBL] [Abstract][Full Text] [Related]
14. A third case of chronic eosinophilic leukemia with the (8;9)(p23;p24) translocation.
Cornfield DB; Gheith SM; Friedman EL
Cancer Genet Cytogenet; 2008 Aug; 185(1):60-1. PubMed ID: 18656698
[No Abstract] [Full Text] [Related]
15. Implication of MAPK1/MAPK3 signalling pathway in t(8;9)(p22;24)/PCM1-JAK2 myelodysplastic/myeloproliferative neoplasms.
Masselli E; Mecucci C; Gobbi G; Carubbi C; Pierini V; Sammarelli G; Bonomini S; Prezioso L; Rossetti E; Caramatti C; Aversa F; Vitale M
Br J Haematol; 2013 Aug; 162(4):563-6. PubMed ID: 23701125
[No Abstract] [Full Text] [Related]
16. A novel fusion of PDGFRB to TSC1, an intrinsic suppressor of mTOR-signaling pathway, in a chronic eosinophilic leukemia patient with t(5;9)(q32;q34).
Zhang Y; Qu S; Wang Q; Li J; Xu Z; Qin T; Huang G; Xiao Z
Leuk Lymphoma; 2018 Oct; 59(10):2506-2508. PubMed ID: 29384404
[No Abstract] [Full Text] [Related]
17. Should myeloid and lymphoid neoplasms with PCM1-JAK2 and other rearrangements of JAK2 be recognized as specific entities?
Bain BJ; Ahmad S
Br J Haematol; 2014 Sep; 166(6):809-17. PubMed ID: 24913195
[TBL] [Abstract][Full Text] [Related]
18. Clinical and cytogenetic remission induced by interferon-alpha in a patient with chronic eosinophilic leukemia associated with a unique t(3;9;5) translocation.
Yamada O; Kitahara K; Imamura K; Ozasa H; Okada M; Mizoguchi H
Am J Hematol; 1998 Jun; 58(2):137-41. PubMed ID: 9625582
[TBL] [Abstract][Full Text] [Related]
19. A Novel PCM1-PDGFRB Fusion in a Patient with a Chronic Myeloproliferative Neoplasm and an ins(8;5).
Ghazzawi M; Mehra V; Knut M; Brown L; Tapper W; Chase A; de Lavallade H; Cross NCP
Acta Haematol; 2017; 138(4):198-200. PubMed ID: 29169164
[No Abstract] [Full Text] [Related]
20. Sustained Response to Ruxolitinib of Eosinophilia-Associated Myeloproliferative Neoplasm with Translocation t(8;9)(p21;p24).
Cai P; Liu S; Duan L; Huo L; Wu D; Chen S; Yang R; Yang X
Acta Haematol; 2023; 146(5):397-400. PubMed ID: 37562364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
